-
Je něco špatně v tomto záznamu ?
Celiac Disease: Promising Biomarkers for Follow-Up
M. Hrunka, L. Janda, M. Šťastná, T. Pinkasová, J. Pecl, L. Kunovský, P. Dítě, P. Jabandžiev
Jazyk angličtina Země Rumunsko
Typ dokumentu časopisecké články, přehledy
NLK
Free Medical Journals
od 2006
Freely Accessible Science Journals
od 2006
Medline Complete (EBSCOhost)
od 2009-09-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
PubMed
38147608
DOI
10.15403/jgld-4926
Knihovny.cz E-zdroje
- MeSH
- bezlepková dieta MeSH
- biologické markery MeSH
- celiakie * MeSH
- deficience IgA * MeSH
- gluteny MeSH
- imunoglobulin A MeSH
- lidé MeSH
- následné studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients' adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000181
- 003
- CZ-PrNML
- 005
- 20240213093014.0
- 007
- ta
- 008
- 240109s2023 rm f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.15403/jgld-4926 $2 doi
- 035 __
- $a (PubMed)38147608
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a rm
- 100 1_
- $a Hrunka, Matěj $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic. . hrunka.matej@fnbrno.cz
- 245 10
- $a Celiac Disease: Promising Biomarkers for Follow-Up / $c M. Hrunka, L. Janda, M. Šťastná, T. Pinkasová, J. Pecl, L. Kunovský, P. Dítě, P. Jabandžiev
- 520 9_
- $a Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients' adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a celiakie $7 D002446
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a deficience IgA $7 D017098
- 650 _2
- $a gluteny $7 D005983
- 650 _2
- $a bezlepková dieta $7 D055050
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a imunoglobulin A $7 D007070
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Janda, Lubomír $u Veterinary Research Institute, Brno, Czech Republic. lubomir.janda@vri.cz
- 700 1_
- $a Šťastná, Michaela $u Veterinary Research Institute, Brno, Czech Republic. michaela.stastna@vri.cz
- 700 1_
- $a Pinkasová, Tereza $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic. pinkasova.tereza@fnbrno.cz
- 700 1_
- $a Pecl, Jakub $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic. pecl.jakub@fnbrno.cz
- 700 1_
- $a Kunovský, Lumír $u 2nd Department of Internal Medicine - Gastroenterology and Geriatrics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc; Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University Brno, Brno; Department of Gastroenterology and Digestive Endoscopy, Masaryk Memorial Cancer Institute, Brno, Czech Republic. lumir.kunovsky@gmail.com
- 700 1_
- $a Dítě, Petr $u Department of Gastroenterology, University Hospital Brno, Faculty of Medicine, Masaryk University Brno, Brno; Department of Internal Medicine and Cardiology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. pdite.epc@gmail.com
- 700 1_
- $a Jabandžiev, Petr $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic. jabandziev.petr@fnbrno.cz
- 773 0_
- $w MED00180296 $t Journal of gastrointestinal and liver diseases $x 1842-1121 $g Roč. 32, č. 4 (2023), s. 536-544
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38147608 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093011 $b ABA008
- 999 __
- $a ok $b bmc $g 2049084 $s 1209875
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 32 $c 4 $d 536-544 $e 20231222 $i 1842-1121 $m Journal of gastrointestinal and liver diseases $n J Gastrointestin Liver Dis $x MED00180296
- LZP __
- $a Pubmed-20240109